Off Label, On Agenda: Gabapentin's Rise and the Debauchery Behind It
Oct 28th 2025 6:38am EDT
Gabapentin’s surge exposes a profit-first system where off-label prescribing, not patient care, drives one of America’s top drugs.
Discuss on Nostr!
Nostr Note ID note10q3ame7kr7jun2c30cs59lp76afn5f308n4qxz90karj3azmwyfswv6sj5 Open on Primal.net Open on Snort.social Open on Iris.to Open on Coracle.social
New to Nostr?
Create an account now & join the conversation!
Promote it on DissentWatch!
- To advertise this post for $0.02 per visit send bitcoins to the address below
- The post will be promoted daily via social media & our "Featured News" display in multiple places
- You can add more anytime
- Ranking order in the Featured News box is based on the balance remaining
Received: 0 mBTC (0.00 USD)
Spent: 0 mBTC (0.00 USD)
Balance: 0 mBTC (0.00 USD)
The amounts above may be lagging behind. If you just sent a payment click below to get more up to date results and push the post to the "Featured News" box faster.